Total Payments
$1,475
2024 Payments
$152.75
Companies
26
Transactions
91
Medicare Patients
2,156
Medicare Billing
$496,724
Payment Breakdown by Category
Food & Beverage$1,462 (99.1%)
Education$13.17 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,462 | 90 | 99.1% |
| Education | $13.17 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $331.48 | 16 | $0 (2024) |
| ABBVIE INC. | $237.02 | 15 | $0 (2023) |
| GENZYME CORPORATION | $115.04 | 7 | $0 (2019) |
| Biogen, Inc. | $114.50 | 8 | $0 (2022) |
| EMD Serono, Inc. | $97.00 | 7 | $0 (2020) |
| Amgen Inc. | $82.49 | 5 | $0 (2019) |
| Allergan, Inc. | $69.09 | 5 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $55.04 | 4 | $0 (2024) |
| Upsher-Smith Laboratories LLC | $41.23 | 2 | $0 (2017) |
| Eisai Inc. | $39.68 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $152.75 | 8 | Novartis Pharmaceuticals Corporation ($62.68) |
| 2023 | $310.55 | 19 | ABBVIE INC. ($140.71) |
| 2022 | $101.59 | 6 | Biogen, Inc. ($47.77) |
| 2021 | $13.83 | 1 | AbbVie Inc. ($13.83) |
| 2020 | $70.26 | 5 | Allergan, Inc. ($29.16) |
| 2019 | $204.51 | 13 | Amgen Inc. ($70.10) |
| 2018 | $266.62 | 17 | Novartis Pharmaceuticals Corporation ($122.69) |
| 2017 | $354.59 | 22 | AbbVie, Inc. ($60.54) |
All Payment Transactions
91 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $29.10 | General |
| Category: Neurology | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: Neurology | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: Neurology | ||||||
| 05/09/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Central Nervous System | ||||||
| 04/09/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: Neurology | ||||||
| 03/21/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.78 | General |
| Category: Neuroscience | ||||||
| 02/28/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: EPILEPSY | ||||||
| 01/12/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Immunology | ||||||
| 12/16/2023 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Neuroscience | ||||||
| 12/11/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Neurology | ||||||
| 10/30/2023 | Microtransponder, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.87 | General |
| 10/18/2023 | Microtransponder, Inc. | — | Food and Beverage | Cash or cash equivalent | $13.11 | General |
| 09/19/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 07/19/2023 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $11.13 | General |
| 07/14/2023 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Neurology | ||||||
| 07/11/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 06/07/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 05/30/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 05/18/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.03 | General |
| Category: Neuroscience | ||||||
| 05/16/2023 | Amneal Pharmaceuticals LLC | LYVISPAH (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: NEUROLOGY | ||||||
| 05/01/2023 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $13.98 | General |
| 04/28/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Neurology | ||||||
| 04/13/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.08 | General |
| Category: NEUROSCIENCE | ||||||
| 03/21/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 02/27/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $4.09 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 605 | 9,326 | $683,297 | $270,922 |
| 2022 | 6 | 505 | 587 | $189,614 | $45,638 |
| 2021 | 8 | 481 | 553 | $163,546 | $45,055 |
| 2020 | 12 | 565 | 7,583 | $399,621 | $135,109 |
Total Patients
2,156
Total Services
18,049
Medicare Billing
$496,724
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 18 | 3,330 | $299,700 | $126,638 | 42.3% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2023 | 11 | 5,100 | $178,500 | $97,935 | 54.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 128 | 128 | $48,640 | $13,706 | 28.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 188 | 243 | $36,450 | $13,472 | 37.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 58 | $12,760 | $4,735 | 37.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 33 | 41 | $20,910 | $3,714 | 17.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 53 | 77 | $17,556 | $3,651 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,880 | $2,529 | 36.8% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 20 | 20 | $39,600 | $1,838 | 4.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 20 | 58 | $9,628 | $903.08 | 9.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 24 | 81 | $8,100 | $874.33 | 10.8% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 28 | 161 | $2,415 | $650.95 | 27.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 13 | $2,158 | $276.90 | 12.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 162 | 162 | $61,560 | $18,445 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 235 | 297 | $44,550 | $16,312 | 36.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 55 | $12,100 | $5,125 | 42.4% |
| 70551 | Mri scan of brain without contrast | Office | 2022 | 32 | 32 | $63,360 | $3,184 | 5.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 27 | $4,320 | $1,492 | 34.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $3,724 | $1,081 | 29.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 210 | 278 | $41,700 | $16,714 | 40.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 128 | 128 | $48,640 | $15,289 | 31.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 53 | $11,660 | $4,918 | 42.2% |
| 70551 | Mri scan brain | Office | 2021 | 20 | 20 | $39,600 | $2,169 | 5.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 19 | 19 | $5,700 | $1,982 | 34.8% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 26 | 26 | $6,916 | $1,857 | 26.9% |
About Dr. Patricia Naslund, M.D
Dr. Patricia Naslund, M.D is a Neurology healthcare provider based in Raleigh, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083643357.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patricia Naslund, M.D has received a total of $1,475 in payments from pharmaceutical and medical device companies, with $152.75 received in 2024. These payments were reported across 91 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($1,462).
As a Medicare-enrolled provider, Naslund has provided services to 2,156 Medicare beneficiaries, totaling 18,049 services with total Medicare billing of $496,724. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Raleigh, NC
- Active Since 06/30/2006
- Last Updated 04/01/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1083643357
Products in Payments
- BOTOX (Biological) $142.21
- KESIMPTA (Drug) $122.03
- LEMTRADA (Drug) $94.65
- UBRELVY (Drug) $90.52
- Aimovig (Biological) $82.49
- Rebif (Biological) $71.64
- AIMOVIG (Biological) $62.36
- Zinbryta (Biological) $60.54
- TYSABRI (Biological) $59.79
- TECFIDERA (Drug) $54.71
- GILENYA (Drug) $44.99
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $41.23
- Leqembi (Drug) $29.10
- ZEPOSIA (Drug) $27.81
- KEVEYIS (Drug) $25.80
- COPAXONE (Drug) $25.52
- MAYZENT (Drug) $21.62
- VYVGART HYTRULO (Drug) $21.46
- AUBAGIO (Drug) $20.39
- Nucynta (Drug) $17.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Raleigh
John Scagnelli, M.d, M.D
Neurology — Payments: $434,945
Neurology $434,945
Dr. Tibor Becske, M.d, M.D
Neurology — Payments: $387,165
Neurology $387,165
Dr. Keith Hull, M.d, M.D
Neurology — Payments: $140,830
Neurology $140,830
Dr. Casey Jeffreys, M.d, M.D
Neurology — Payments: $70,215
Neurology $70,215
John Collins, M.d, M.D
Neurology — Payments: $25,595
Neurology $25,595
Dr. Kenneth Carnes, M.d, M.D
Neurology — Payments: $23,277
Neurology $23,277